This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Bear markets test retirement portfolios. This piece explains how risk parity may influence drawdowns and resilience, plus practical steps for retirees.
28,208 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Netflix faces a pivotal July 16 earnings date. This article breaks down the three main reasons the stock needs convin...
Is UPS stock a long-term winner? This guide breaks down the turnaround story, real numbers, and a clear plan for eval...
Oracle is leaning into AI infrastructure with its database expertise, cloud platform, and data-center plans. This art...
Hewlett Packard Enterprise just blew past expectations with stronger revenue and profits, stoking the AI server rally...
Rocket Lab has surged more than 350% in a year, but investors remain split on the sustainability of the rally as back...
A high-profile insider sale at Sonic Automotive sparks questions about executive shareholdings and stock outlook. Thi...
Roblox faces a tough year in the market, but a rebound isn’t off the table. This guide breaks down the business, risk...
ServiceNow sprinted higher on Friday as AI and automation headlines fueled optimism. This piece breaks down the catal...
Bitcoin rose above $60,000, yet a large inflow of BTC to exchanges suggests the rebound could face renewed selling pr...
When a tech titan reshuffles its gaming division, investors pay attention. This article breaks down the potential sto...
Memory prices are showing signs of life, and a small-cap memory company could ride the wave. This article explains wh...